home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

244.48 +1.53 (+0.63%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 06, 2025

Via Benzinga

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 04, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

July 22, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 07, 2025

Via Benzinga

Peering Into Ascendis Pharma's Recent Short Interest ↗

July 03, 2025

Via Benzinga

Is Ascendis Pharma Gaining or Losing Market Support? ↗

June 03, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

May 29, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

A Glimpse of Ascendis Pharma's Earnings Potential ↗

April 30, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

June 12, 2025

Via Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

May 21, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗

May 06, 2025

Via Benzinga

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗

May 05, 2025

Via Benzinga

Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria ↗

April 28, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?

Via Chartmill

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗

March 04, 2025

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

February 19, 2025

Via Benzinga

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

January 23, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

April 15, 2025

Via Benzinga

Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock? ↗

April 04, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).

Via Chartmill

Looking Into Ascendis Pharma's Recent Short Interest ↗

March 26, 2025

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

March 25, 2025

Via Benzinga

Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock? ↗

March 14, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).

Via Chartmill

Why Is BioMarin Stock Trading Higher On Thursday? ↗

February 20, 2025

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Via Benzinga

Looking Into Ascendis Pharma's Recent Short Interest ↗

January 15, 2025

Via Benzinga

Peering Into Ascendis Pharma's Recent Short Interest ↗

December 03, 2024

Via Benzinga

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗

February 13, 2025

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Via Stocktwits

This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

January 07, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com